A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A01N 1/00 (2006.01) A01N 1/02 (2006.01) A01N 63/00 (2006.01) A61K 39/00 (2006.01) C07K 16/28 (2006.01)
Patent
CA 2350064
The use of a chimeric anti-CD20 antibody, RITUXAN~, as an in vivo or in vitro purging agent, of patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related malignancies, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
L'invention concerne l'utilisation d'un anticorps chimère anti-CD20, RITUXAN~, en tant qu'agent de purge in vivo ou in vitro, chez des patients récepteurs de greffes de moelle osseuse et de cellules souches de sang périphérique, pendant le traitement de malignités relatives aux cellules bêta, telles que les lymphomes B ou les leucémies. Ledit agent de purge peut favoriser la prise de la greffe et/ou empêcher la rechute chez lesdits patients.
Grillo-Lopez Antonio J.
Leonard John E.
Biogen Idec Inc.
Gowling Lafleur Henderson Llp
Idec Pharmaceuticals Corporation
LandOfFree
Chimeric anti-cd20 antibody treatment of patients receiving... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric anti-cd20 antibody treatment of patients receiving..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric anti-cd20 antibody treatment of patients receiving... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1451073